 Galapagos NV NASDAQ: GLPG has announced interim results from two ongoing safety studies investigating the effect of Jyseleca filgotinib on sperm parameters in males with inflammatory bowel disease MANTA study or rheumatic conditions MANTA-RAy study. Out of the 248 randomized patients, 240 reached Week 13 with two evaluable semen samples at baseline and Week 13. 